E Munzone1, A Giobbie-Hurder2, B A Gusterson3, E Mallon4, G Viale5, B Thürlimann6, B Ejlertsen7, G MacGrogan8, F Bibeau9, G Lelkaitis10, K N Price11, R D Gelber12, A S Coates13, A Goldhirsch14, M Colleoni15. 1. Division of Medical Senology, European Institute of Oncology, Milan, Italy elisabetta.munzone@ieo.it. 2. Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA. 3. Institute of Cancer Sciences, Glasgow University, Glasgow. 4. Southern General Hospital, Glasgow, UK. 5. Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy. 6. Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. 7. Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark. 8. Department of Pathology, Institut Bergonié, Bordeaux. 9. Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France. 10. Department of Pathology, Rigshospitalet, Copenhagen, Denmark. 11. International Breast Cancer Study Group (IBCSG) Statistical Center. 12. Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA. 13. International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia. 14. Program of Breast Health, European Institute of Oncology, Milan, Italy. 15. Division of Medical Senology, European Institute of Oncology, Milan, Italy.
Abstract
BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years. RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06]. CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease. CLINICALTRIALSGOV: NCT00004205.
BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years. RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06]. CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease. CLINICALTRIALSGOV: NCT00004205.
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: Giuseppe Viale; Anita Giobbie-Hurder; Meredith M Regan; Alan S Coates; Mauro G Mastropasqua; Patrizia Dell'Orto; Eugenio Maiorano; Gaëtan MacGrogan; Stephen G Braye; Christian Ohlschlegel; Patrick Neven; Zsolt Orosz; Wojciech P Olszewski; Fiona Knox; Beat Thürlimann; Karen N Price; Monica Castiglione-Gertsch; Richard D Gelber; Barry A Gusterson; Aron Goldhirsch Journal: J Clin Oncol Date: 2008-11-03 Impact factor: 44.544
Authors: Sara H Javid; Barbara L Smith; Erica Mayer; Jennifer Bellon; Colleen D Murphy; Stuart Lipsitz; Mehra Golshan Journal: Am J Surg Date: 2008-09-11 Impact factor: 2.565
Authors: B Weigelt; H M Horlings; B Kreike; M M Hayes; M Hauptmann; L F A Wessels; D de Jong; M J Van de Vijver; L J Van't Veer; J L Peterse Journal: J Pathol Date: 2008-10 Impact factor: 7.996
Authors: Tarek M A Abdel-Fatah; Desmond G Powe; Zsolt Hodi; Jorge S Reis-Filho; Andrew H S Lee; Ian O Ellis Journal: Am J Surg Pathol Date: 2008-04 Impact factor: 6.394
Authors: Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen Journal: J Natl Cancer Inst Date: 2009-05-12 Impact factor: 13.506
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976